Understanding how TEAD and VGLL proteins work together in cancer and development
Official title: Novel regulation and functions of TEAD-VGLL complex
Funded at Massachusetts General Hospital · NIH-11162729 · Data updated 2026-11-12
This study is looking at a specific protein complex that affects how cancer cells grow and respond to treatments, with the goal of finding new ways to help patients get better care and improve their treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $680,594 |
| NIH project number | 1R01CA290785-01A1 |
| Project ID | NIH-11162729 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that exhibit resistance to current therapies, particularly those related to the TEAD-VGLL signaling pathway.
✕Less likely to help
Patients with conditions unrelated to cancer or those not expressing the TEAD-VGLL complex may not benefit from this research.
What this research studies
This research investigates the TEAD-VGLL complex, which plays a crucial role in regulating gene expression related to cancer and development. By examining the structure and functions of this complex, the researchers aim to uncover how it contributes to resistance against certain cancer treatments. The study will also focus on developing new inhibitors that can effectively target this complex, potentially leading to better therapeutic options for patients. Patients may benefit from insights gained about cancer biology and new treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve outcomes for cancer patients by targeting the TEAD-VGLL complex.
How similar studies have gone: Previous research has shown promising results in targeting similar protein complexes in cancer, suggesting potential for success in this novel approach.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Wu, Xu — Massachusetts General Hospital
- Study coordinator: Wu, Xu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.